← All trials
NCT06532552
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 29, 2024
- Primary completion
- Aug 1, 2027
- Completion date
- Aug 1, 2028
- First posted
- Aug 1, 2024
- Last posted
- Aug 1, 2024
- Enrollment
- 172
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Soochow UniversityLead sponsor
- Bengbu Medical CollegeCollaborator
- Qingdao UniversityCollaborator
- Shandong UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Soochow UniversitySponsor investigator
- Huazhong University of Science and TechnologyCollaborator
- Soochow UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.